Role of Ormeloxifene (Centchroman) in Benign Mastalgia of Diverse Origin

Mastalgia is a commonly encountered complaint in everyday gynaecological practice. Although various options were suggested by different authorities none of them stood the test of time and mastalgia remains a treatment quandary. We have selected Ormeloxifene as a treatment modality for mastalgia of benign origin because of its selective anti-estrogenic property. Women with mastalgia attending the Gynaecology OPD between ages 20-50yrs fulfilling the inclusion criteria were registered for the study. The patients were started on Ormeloxifene 60mg twice weekly for three months after excluding the possibilities of malignancy. The results were recorded on a pain score of grade 0 to 4 which was devised by the author. Out of total 84 patients studied between August 2009 and August 2011, severe pain was recorded in 72.6%patients (grade 3 & 4). The rest 27.4%patients had less severe pain (grade 1 & 2). The mammographic lesions noted either singly or in combinations were fibroadenosis 69%, fibroadenoma 11.9%, duct ectasia 4.8%, benign cysts 10.7%, and benign micro calcifications of 11.9%. 21.4% had normal mammography. Excellent response to the treatment was noticed in most. 57.14% were pain free at the end of one month; 82.14% by the end of second month, and a whopping 92.8% had no pain by the end of third month. 4.8% persisted with mild pain. In 2.4% no change in the severity was noted. The adverse effects noted were 8.33% of either oligomenorrhoea or hypo-menorrhoea, 2.38% of menorrhagia and 2.38% of hot flushes. This study suggests that Ormeloxifene may be considered as a safe, efficient and cost-effective non-steroidal drug for the treatment of mastalgia with minimal adverse effects.